In vitro activity of mirincamycin (U24729A) against Plasmodium falciparum isolates from Gabon.
We assessed the in vitro activity of mirincamycin, a lincosamide antibiotic, against Plasmodium falciparum clinical isolates from Gabon. Growth was determined by HRP2 enzyme-linked immunosorbent assay using an adapted protocol with a prolonged incubation time (6 days) to account for antibiotic-induced delayed death. Mirincamycin's cis and trans isomers are more active (median 50% inhibitory concentrations [IC(50)s], 3.2 nM and 2.6 nM) than the comparator drugs clindamycin (IC(50), 12 nM) and doxycycline (IC(50), 720 nM), and therefore, further clinical development is promising.
Institute of Tropical Medicine, University of Tübingen, Tübingen, Germany.
Jana
J
Held
Richard
R
Westerman
Peter G
PG
Kremsner
Benjamin
B
Mordmüller
D000818:Animals; D000962:Antimalarials / Q000737:chemistry / Q000494:pharmacology*; D002981:Clindamycin / Q000031:analogs & derivatives* / Q000737:chemistry / Q000494:pharmacology; D004318:Doxycycline / Q000494:pharmacology; D004797:Enzyme-Linked Immunosorbent Assay; D005681:Gabon; D016778:Malaria, Falciparum / Q000469:parasitology; D010963:Plasmodium falciparum / Q000187:drug effects*; D013237:Stereoisomerism
D000962:Antimalarials; D002981:Clindamycin; C000867:mirincamycin; D004318:Doxycycline